1. Home
  2. RMCF vs KALA Comparison

RMCF vs KALA Comparison

Compare RMCF & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rocky Mountain Chocolate Factory Inc.

RMCF

Rocky Mountain Chocolate Factory Inc.

HOLD

Current Price

$1.12

Market Cap

14.9M

ML Signal

HOLD

Logo KALA BIO Inc.

KALA

KALA BIO Inc.

HOLD

Current Price

$0.70

Market Cap

13.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RMCF
KALA
Founded
1981
2009
Country
United States
United States
Employees
N/A
6
Industry
Specialty Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.9M
13.3M
IPO Year
2024
2017

Fundamental Metrics

Financial Performance
Metric
RMCF
KALA
Price
$1.12
$0.70
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$31.50
AVG Volume (30 Days)
4.3M
56.8K
Earning Date
06-16-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
34.88
67.39
EPS
N/A
N/A
Revenue
$30,432,352.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.66
$0.07
52 Week High
$2.99
$20.58

Technical Indicators

Market Signals
Indicator
RMCF
KALA
Relative Strength Index (RSI) 50.41 29.61
Support Level $0.75 $0.56
Resistance Level $1.19 $0.72
Average True Range (ATR) 0.22 0.12
MACD -0.00 0.01
Stochastic Oscillator 32.21 4.41

Price Performance

Historical Comparison
RMCF
KALA

About RMCF Rocky Mountain Chocolate Factory Inc.

Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The company prepares numerous products, including caramel apples in the store. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, and Others. The company derives maximum revenue through manufacturing activities. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.

About KALA KALA BIO Inc.

Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Share on Social Networks: